[HTML][HTML] Comparison of clinical outcomes following gefitinib and erlotinib treatment in non–small-cell lung cancer patients harboring an epidermal growth factor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park… - Journal of Thoracic …, 2014 - Elsevier
Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer …
Background Epidermal growth factor receptor (EGFR) mutations are associated with
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
sensitivity to gefitinib or erlotinib in non-small cell lung cancer (NSCLC). We investigated the …
Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations
Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …
EGFR exon 19 deletion is associated with favorable overall survival after first-line gefitinib therapy in advanced non–small cell lung cancer patients
YW Choi, SY Jeon, GS Jeong, HW Lee… - American journal of …, 2018 - journals.lww.com
Objectives: Exon 19 deletion and L858R mutation in exon 21 of the epidermal growth factor
receptor (EGFR) are both common mutations that predict a good response to EGFR tyrosine …
receptor (EGFR) are both common mutations that predict a good response to EGFR tyrosine …
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation
S Igawa, M Kasajima, M Ishihara, M Kimura, Y Hiyoshi… - Oncology, 2014 - karger.com
Background: Exon 19 deletion and L858R point mutation of the epidermal growth factor
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …
receptor (EGFR) are the most commonly encountered EGFR mutations in non-small cell …
First-or second-line therapy with gefitinib produces equal survival in non–small cell lung cancer
JY Wu, CJ Yu, CH Yang, SG Wu, YH Chiu… - American journal of …, 2008 - atsjournals.org
Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC)
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in …
[HTML][HTML] Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating …
WS Wu, YM Chen, CM Tsai… - Experimental and …, 2012 - spandidos-publications.com
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
treatment for advanced non-small cell lung cancer. The objective of the present study was to …
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations
K Asami, T Okuma, T Hirashima, M Kawahara, S Atagi… - Lung Cancer, 2013 - Elsevier
BACKGROUND: Gefitinib is an effective treatment for patients with non-small cell lung
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
cancer who harbor activating epidermal growth factor receptor (EGFR) mutations. However …
相关搜索
- clinical outcomes gefitinib and erlotinib
- clinical outcomes either exon
- growth factor either exon
- growth factor receptor mutation
- clinical outcomes growth factor
- erlotinib treatment either exon
- receptor mutation either exon
- clinical outcomes receptor mutation
- growth factor erlotinib treatment
- erlotinib treatment receptor mutation
- egfr mutations gefitinib and erlotinib
- gefitinib and erlotinib in patients
- gefitinib or erlotinib prolonged survival
- pooled analysis gefitinib and erlotinib
- clinical outcomes pooled analysis
- egfr mutations pooled analysis